Clinical trialPhase 1Withdrawn
A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
A Phase Ib Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma
- Outcome
- Stopped earlyLack of Funding (Business decision)
- Phase
- Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Start
- January 2021
- Expected end
- November 2022
- Enrollment
- 0 participants
- Sites
- 0
- Primary outcomes
- Dose limiting toxicity (DLT)
- Sponsor
- Other
- Results posted
- No
- Last update
- 15 January 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.